{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:11:12Z","timestamp":1778667072719,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["420008\/2018\\u20137"],"award-info":[{"award-number":["420008\/2018\\u20137"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009648","name":"National Health Fund","doi-asserted-by":"publisher","award":["17217.9850001\\u201315-006"],"award-info":[{"award-number":["17217.9850001\\u201315-006"]}],"id":[{"id":"10.13039\/100009648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["PPM-00366-18"],"award-info":[{"award-number":["PPM-00366-18"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.thromres.2025.109336","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:31:32Z","timestamp":1746099092000},"page":"109336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study"],"prefix":"10.1016","volume":"250","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0297-1455","authenticated-orcid":false,"given":"Vivian Karla Brognoli","family":"Franco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9025-0289","authenticated-orcid":false,"given":"Ricardo Mesquita","family":"Camelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-7099","authenticated-orcid":false,"given":"Ma\u00edse Moreira","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7727-5000","authenticated-orcid":false,"given":"Andrea Gon\u00e7alves de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Vilela de Oliveira","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6662-4623","authenticated-orcid":false,"given":"Cl\u00e1udia Santos","family":"Lorenzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Stephanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3637-9791","authenticated-orcid":false,"given":"Ros\u00e2ngela de Albuquerque","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-1480","authenticated-orcid":false,"given":"Nath\u00e1lia Martins","family":"Beserra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0210-0721","authenticated-orcid":false,"given":"Juliana Alvares","family":"Teodoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-7093","authenticated-orcid":false,"given":"Suely Meireles","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2025.109336_bb0005","series-title":"Report on the Annual Global Survey 2022","author":"World Federation of Hemophilia","year":"2023"},{"issue":"3","key":"10.1016\/j.thromres.2025.109336_bb0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4155\/cli.14.122","article-title":"Immune tolerance induction in hemophilia","volume":"5","author":"Mancuso","year":"2015","journal-title":"Clin. Invest. (Lond)."},{"key":"10.1016\/j.thromres.2025.109336_bb0015","author":"BRASIL"},{"issue":"11","key":"10.1016\/j.thromres.2025.109336_bb0020","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/17474086.2018.1521718","article-title":"The importance of inhibitor eradication in clinically complicated hemophilia A patients","volume":"11","author":"Oldenburg","year":"2018","journal-title":"Expert Rev. Hematol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109336_bb0025","first-page":"369","article-title":"Impacto econ\u00f3mico de los inhibidores em hemofilia tipo A pedi\u00e1trica","volume":"155","author":"L\u00f3pez-Facundo","year":"2019","journal-title":"Gac. Med. Mex."},{"issue":"4","key":"10.1016\/j.thromres.2025.109336_bb0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.15053","article-title":"How I manage patients with inherited hemophilia A and B and factor inhibitors","volume":"180","author":"Ljung","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.thromres.2025.109336_bb0035","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3111\/13696998.2014.953679","article-title":"Costs and utilization of hemophilia a and B patients with and without inhibitors","volume":"17","author":"Armstrong","year":"2014","journal-title":"J. Med. Econ."},{"issue":"8","key":"10.1016\/j.thromres.2025.109336_bb0040","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/03007995.2019.1596437","article-title":"Healthcare costs among patients with hemophilia A treated with factor replacement or bypassing agents","volume":"35","author":"Swindle","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.thromres.2025.109336_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13023-019-1175-5","article-title":"Hemophilia A: health and economic burden of a rare disease in Portugal","volume":"14","author":"Caf\u00e9","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.thromres.2025.109336_bb0050","first-page":"164","article-title":"Cost of patients with Hemophilia A and high-titer inhibitors in Colombia","volume":"20","author":"S\u00e1nchez-Vanegas","year":"2019","journal-title":"Value in Health Reg Issues"},{"key":"10.1016\/j.thromres.2025.109336_bb0055","series-title":"Minist\u00e9rio da Sa\u00fade. Portaria n\u00b0 1.114, de 16 de novembro de 2021. Protocolo de Uso de Indu\u00e7\u00e3o de Imunotoler\u00e2ncia para Indiv\u00edduos com hemofilia A e Inibidor","author":"BRASIL","year":"2021"},{"issue":"8","key":"10.1016\/j.thromres.2025.109336_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256265","article-title":"Predictors of the outcome of immune tolerance induction in patients with hemophilia A and inhibitors: the Brazilian Immune Tolerance (BrazIT) Study protocol","volume":"16","author":"Camelo","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.thromres.2025.109336_bb0065","author":"BRASIL"},{"issue":"6","key":"10.1016\/j.thromres.2025.109336_bb0070","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"International immune tolerance study. The principal results of the international immune tolerance study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2025.109336_bb0075","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"J. Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.thromres.2025.109336_bb0080","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s00277-020-04250-9","article-title":"Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting","volume":"99","author":"Ay","year":"2020","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109336_bb0085","first-page":"434","article-title":"Hemovida Web Coagulopatias: um relato do seu processo de desenvolvimento e implanta\u00e7\u00e3o","volume":"18","author":"Barca","year":"2010","journal-title":"Cad. sa\u00fade colet. (Rio J.)."},{"key":"10.1016\/j.thromres.2025.109336_bb0090","author":"BRASIL"},{"key":"10.1016\/j.thromres.2025.109336_bb0095","author":"International Monetary Fund"},{"issue":"22","key":"10.1016\/j.thromres.2025.109336_bb0100","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood.V128.22.4758.4758","article-title":"The Immune Tolerance Induction Factor Utilizations and Costs for the Management of male Hemophilia A Patients who Developed Inhibitors. 58th ASH Annual Meeting Abstracts","volume":"128","author":"Su","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2025.109336_bb0105","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1111\/hae.13294","article-title":"Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis","volume":"23","author":"Kenet","year":"2017","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2025.109336_bb0110","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1111\/hae.13173","article-title":"Making economic evaluations more helpful for treatment choices in hemophilia","volume":"23","author":"Drummond","year":"2017","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.thromres.2025.109336_bb0115","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/hae.14347","article-title":"Real-world cost estimates of initiating emicizumab in US patients with haemophilia A","volume":"27","author":"Samelson-Jones","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.thromres.2025.109336_bb0120","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/hae.14143","article-title":"Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea","volume":"27","author":"Lee","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109336_bb0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.vhri.2022.10.007","article-title":"Economic evaluation of immune tolerance induction in children with severe hemophilia A and high-responding inhibitors: a cost-effectiveness analysis of prophylaxis with emicizumab","volume":"34","author":"Camelo","year":"2022","journal-title":"Value Health Reg Issues."},{"issue":"5","key":"10.1016\/j.thromres.2025.109336_bb0130","first-page":"1334","article-title":"Emicizumab: the hemophilia A game-changer","volume":"109","author":"Alcedo Andrade","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.thromres.2025.109336_bb0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/hae.12780","article-title":"European Haemophilia Therapy Strategy Board (EHTSB); European Haemophilia Therapy Strategy Board EHTSB. Immune tolerance induction in patients with haemophilia A and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study)","volume":"22","author":"Rocino","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109336_bb0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2516.2006.01296.x","article-title":"Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors","volume":"12","author":"Astermark","year":"2006","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109336_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01497.x","article-title":"International workshop on immune tolerance induction: consensus recommendations","volume":"13","author":"DiMichele","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109336_bb0150","doi-asserted-by":"crossref","unstructured":"Kempton C.L, Fedewa SA. Defining the impact of immune tolerance induction on clinically relevant outcomes in a US cohort of severe hemophilia a. Blood Adv. 2024 Mar; 8(5): 1190\u20131199. doi:https:\/\/doi.org\/10.1182\/bloodadvances.2023011974.","DOI":"10.1182\/bloodadvances.2023011974"},{"issue":"4","key":"10.1016\/j.thromres.2025.109336_bb0155","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"Carcao","year":"2019","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2025.109336_bb0160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17474086.2021.1875817","article-title":"Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia a patients with inhibitors","volume":"14","author":"Carcao","year":"2021","journal-title":"Expert Rev. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109336_bb0165","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018","volume":"19","author":"Hassan","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109336_bb0170","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/hae.12621","article-title":"Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment","volume":"21","author":"Earnshaw","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109336_bb0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CEOR.S25909","article-title":"Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran","volume":"3","author":"Rasekh","year":"2011","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"6","key":"10.1016\/j.thromres.2025.109336_bb0180","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1097\/MPH.0000000000001391","article-title":"Low-dose immune tolerance induction in hemophilia: a single-center experience","volume":"41","author":"Zulfikar","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109336_bb0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.14456","article-title":"Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success","volume":"28","author":"Elalfy","year":"2022","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2025.109336_bb0190","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/MBC.0000000000000366","article-title":"Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country","volume":"27","author":"Ay","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825000854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825000854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:20:52Z","timestamp":1778664052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825000854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"alternative-id":["S0049384825000854"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109336","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109336"}}